Nab-paclitaxel

Identifier: CI-DRUG-00000397
Entity page: /drug/nab-paclitaxel ↗
Edges: 981

Neighbours: 15 cancers10 trials
Drawn: 25 of 25 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Nab-paclitaxel investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 228show all (up to 200)
→ investigated in trials for	Malignant Pancreatic Neoplasm 167 trials (62 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Pancreatic Neoplasm	167	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasm

Nab-paclitaxel studied in …STUDIED_INderived10 of 753show all (up to 200)
→ studied in	NCT03734029Phase 3 · completed Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] · 753 trials list this drug (282 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07060807Phase 3 · recruiting A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) · 753 trials list this drug (282 active)	—	—	Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07621718Phase 3 · recruiting Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) · 753 trials list this drug (282 active)	—	—	Malignant Pancreatic Neoplasm,Pancreatic Adenocarcinoma,Pancreatic Adenosquamous Carcinoma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT04253964Phase 2 · recruiting Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy · 753 trials list this drug (282 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06103864Phase 3 · recruiting A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) · 753 trials list this drug (282 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06312176Phase 3 · recruiting A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) · 753 trials list this drug (282 active)	—	—	Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06841354Phase 3 · recruiting A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) · 753 trials list this drug (282 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07259317Phase 2 · recruiting Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma · 753 trials list this drug (282 active)	—	—	Carcinoma,Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06018337Phase 3 · active not recruiting A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) · 753 trials list this drug (282 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06096844Phase 3 · recruiting Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial · 753 trials list this drug (282 active)	—	—	Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths